Earlier this week, a press release from Alnylam Pharmaceuticals, Inc, announced the that the phase 3 study of their experimental acute hepatic porphyria drug Givosiran yielded
The Amyloidosis Foundation
The Amyloidosis Foundation began with the vision of two patients, Don Brockman and Dennis Krysmalski, to support research and patients in the amyloidosis community. The Foundation prioritizes raising awareness for earlier diagnosis, educating medical personnel, and empowering patient advocacy through various services.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With The Amyloidosis Foundation
Patient Worthy Posts on Amyloidosis
Familial Chylomicronemia Syndrome Familial chylomicronemia syndrome (FCS) is a condition that is considered ultra-rare. It’s caused when the enzyme called lipoprotein lipase (LPL) is impaired.
About BridgeBio Pharma BridgeBio Pharmaceuticals was created in 2015 by veterans from the fields of academia and biotechnology. The company focuses on the development of
AL Amlyoidosis is a rare disease which causes a buildup of harmful proteins (amyloids) in organs such as the kidneys and the heart. This accumulation causes
Ionis Pharmaceuticals and Roche have been collaborating on a drug for Huntington’s Disease which will treat the root cause of the condition. Currently, there are
Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It’s just been published that